Apokyn — United Healthcare
Acute, intermittent treatment of 'off' episodes associated with advanced Parkinson’s disease
Initial criteria
- Diagnosis of Parkinson’s disease
- Used as intermittent treatment for OFF episodes
Reauthorization criteria
- Documentation of positive clinical response to Apokyn therapy
Approval duration
Initial: 6 months; Reauthorization: 12 months